title: Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report.
abstract: Interferon (IFN) therapy is nowadays widely used in clinical practice. In the literature, there are very few reports of the association between IFN therapy and pulmonary arterial hypertension (PAH), and current guidelines do not mention IFNs as a risk factor for PAH. We describe a patient with multiple sclerosis who developed severe PAH after treatment with IFN-β-1a and the clinical response to sildenafil. Furthermore, we stress the need to further investigate the link between IFNs and PAH.
authors.affiliation: Pulmonary Hypertension Center, Bassini Hospital, Azienda Ospedaliera Istituti Clinici di Perfezionamento, Cinisello Balsamo, Milan, Italy.
authors.forename: Sergio
authors.initials: S
authors.lastname: Caravita
authors.forename: Maria Beatrice
authors.initials: MB
authors.lastname: Secchi
authors.forename: Sheng Chin
authors.initials: SC
authors.lastname: Wu
authors.forename: Simona
authors.initials: S
authors.lastname: Pierini
authors.forename: Anita
authors.initials: A
authors.lastname: Paggi
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000188:drug therapy; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D000959:Antihypertensive Agents; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D016899:Interferon-beta; D000068677:Sildenafil Citrate; D000068556:Interferon beta-1a